Serotonin toxicity, MAO inhibitors, antidepressants and diphenhydramine.
Serotonin toxicity: clinical cases
Serotonin toxicity involving DXM is described in clinical publications. It should be presented as a documented complication, particularly in combinations with serotonergic agents.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Monte reviews overdose cases involving products with DXM and chlorpheniramine. Harada describes a fatal case involving overdose of DXM and moclobemide. The Auvelity label also carries a warning.
Limits of the conclusion: Clinical cases establish that the complication can occur; its frequency across all doses and combinations is difficult to determine from them.
Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 The FAQ places serotonin syndrome under a theoretical heading, although its text already discusses hazardous combinations.
The warning remains applicable and deserves prominent presentation. Modern clinical reports and prescription labeling add to the historical basis.
Retained
According to the 2026 audit · edition
Evidence and limitations
What was examined: Harada describes a fatal case involving moclobemide. The Auvelity label contraindicates combination with MAO inhibitors and includes specific provisions for linezolid and intravenous methylene blue.
Limits of the conclusion: Specific medicine restrictions are checked against the current label for the product concerned. This section examines the historical text.
It is important to distinguish changes in DXM exposure from the combination’s serotonergic effects. Both pathways matter for fluoxetine and paroxetine.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Chyka’s clinical guideline accounts for interacting medicines; the Auvelity label includes a serotonin-syndrome warning and information about CYP2D6 inhibition.
Limits of the conclusion: The pathways can coexist. Their contribution depends on the particular medicine, regimen and other ingredients.
That broad judgment should be removed. Diphenhydramine’s own sedative and antimuscarinic effects matter, as does its inhibition of CYP2D6.
Corrected
According to the 2026 audit · edition
Evidence and limitations
What was examined: Hamelin demonstrated effects of diphenhydramine on CYP2D6-dependent metoprolol metabolism in humans. Chyka’s guideline calls for considering accompanying ingredients in DXM poisoning.
Limits of the conclusion: Hamelin’s study used metoprolol. Quantifying the interaction directly with DXM requires its own data.